Antibodies against GPR64 and uses thereof
View Patent ↗GPR64 antibody compositions are provided. These antibodies may be used for diagnosis or treatment of cancer, especially ovarian cancer, Ewing's sarcoma, uterine cancer, and other GPR64 expressing tumor types.
1. A hybridoma cell line deposited as ATCC Accession Number PTA-5704.
2. An antibody produced by the hybridoma cell line of claim 1 .
3. An antigen binding fragment of the antibody of claim 2 .
4. The antigen binding fragment of claim 3 , selected from the group consisting of Fab, Fab′, F(ab′) 2 , and Fv fragments.
5. A conjugate comprising the antibody of claim 2 , wherein the antibody is conjugated to an effector moiety.
6. The conjugate of claim 5 , wherein the effector moiety is selected from the group consisting of: a fluorescent label, a radioisotope and a cytotoxic agent.
7. The conjugate of claim 6 , wherein the cytotoxic agent is selected from the group consisting of: diphtheria A chain, exotoxin A chain, ricin A chain, abrin A chain, curcin, crotin, phenomycin, neomycin, and auristatin.
8. The conjugate of claim 7 , wherein the cytotoxic agent is auristatin.
9. The conjugate of claim 6 , wherein the radioisotope is selected from the group consisting of 3 H, 14 C, 32 P, 35 S, 125 I, 131 I 90 Y and 186 Re.
10. The antibody of claim 2 , wherein the antibody binds a polypeptide having the amino acid sequence of SEQ ID NO:2.
11. The antibody of claim 10 , wherein the polypeptide is localized to the cell surface of a cancer cell.
12. The antibody of claim 11 , wherein the antibody inhibits growth of the cancer cell.
13. A. pharmaceutical composition comprising a pharmaceutically acceptable excipient and the antibody of claim 2 .
14. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the conjugate of claim 8 .
15. An antibody produced by a hybridoma cell line having ATCC Accession number PTA-5704.
16. A diabody comprising a first polypeptide comprising the heavy chain variable domain (V H ) of the antibody of claim 2 and further comprising a second polypeptide comprising the light chain variable domain (V L ) of the antibody of claim 2 , wherein said diabody comprises an antigen binding domain that binds to a polypeptide comprising the amino acid sequence of SEQ ID NO: 2.
17. A single chain antibody comprising the heavy chain variable domain (V H ) of the antibody of claim 2 and the light chain variable domain (V L ) of the antibody of claim 2 , wherein said single chain antibody binds to a polypeptide comprising the amino acid sequence of SEQ ID NO: 2.
18. A chimeric antibody comprising a first polypeptide comprising the heavy chain variable domain (V H ) of the antibody of claim 2 and further comprising a second polypeptide comprising the light chain variable domain (V L ) of the antibody of claim 2 , wherein said chimeric antibody binds to a polypeptide comprising the amino acid sequence of SEQ ID NO: 2.
19. A humanized antibody comprising a first polypeptide comprising each of the three complementarity determining regions (CDRs) of the heavy chain variable domain (VH) of the antibody of claim 2 and further comprising a second polypeptide comprising each of the three CDRs of the light chain variable domain (V L ) of the antibody of claim 2 , wherein said humanized antibody binds to a polypeptide comprising the amino acid sequence of SEQ ID NO: 2.
20. The conjugate of claim 5 , wherein the antibody binds a polypeptide having the amino acid sequence of SEQ ID NO: 2.